Venture Capital Deals and Investments
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Venture Capital Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
Nilo Therapeutics Raises $101M Series A to Advance Neural-Circuit Therapies
Series AVenture Capital

Nilo Therapeutics Raises $101M Series A to Advance Neural-Circuit Therapies

•October 17, 2025
•Oct 17, 2025
0

Participants

Nilo Therapeutics

Nilo Therapeutics

company

The Column Group

The Column Group

investor

DCVC

DCVC

investor

Lux Capital

Lux Capital

investor

Bill & Melinda Gates Foundation

Bill & Melinda Gates Foundation

investor

Alexandria Real Estate Equities

Alexandria Real Estate Equities

investor

Deal Summary

Nilo Therapeutics launched with a $101M Series A to develop neural-circuit approaches for restoring immune homeostasis. The round was led by The Column Group, DCVC Bio and Lux Capital, with participation from the Gates Foundation and Alexandria Venture Investments; Kim Seth, Ph.D. was named CEO.

0

Comments

Want to join the conversation?

Loading comments...